Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Farkasgyepu, Hungary Clinical Trials

A listing of Farkasgyepu, Hungary clinical trials actively recruiting patients volunteers.

RESULTS

Found (3859) clinical trials

Subjects with RRMS who have experienced a relapse and who will receive 3 to 5 (given over a period of up to 7 days) days of treatment with high dose steroids (oral or IV) within 10 days of the onset of relapse symptoms are candidates for the current study. At ...

Phase

This study will be comparing two currently marketed medication for COPD using two different inhaler devices.

Phase

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric subjects = 17 years of age and at least 9 [20%] obese subjects with ...

Phase

The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. The effect of UMC/VI, UMEC, and salmeterol with respect to patient HRQoL measured through patient reported outcomes (PROs) Questionnaires, symptoms and lung function will also be ...

Phase

Northern California research is looking for participants who have a diagnosis of gout to participate in a new study. Participants must be ages 18-85 and taking medication to control their uric acid levels. The study being conducted is for an already FDA approved medication that would be taken in combination ...

Phase

The drug being tested in this study is called Vedolizumab. Vedolizumab will be administered as an IV infusion. It is being tested in this study with new doses. This study will investigate the efficacy and safety of dose optimization of vedolizumab IV, compared with standard dosing of vedolizumab IV, over ...

Phase

This is a prospective, longitudinal, non-interventional study in an adult population (age ≥ 18 years) of men and women who have been diagnosed with select subcategories of either MF or ET. Patients will be enrolled over approximately 24 months and observed for a minimum of 36 months from enrollment.

Phase

Protocol # MNK14274069 This is a multicenter, multiple dose study to estimate the response rate, and examine the safety of, Acthar in subjects with RRMS who have not responded to high dose intravenous methylprednisolone (IVMP), oral prednisone, or oral methylprednisolone. Approximately 66 subjects will be randomized.

Phase

This is a phase 4, open-label, multicenter study to investigate the efficacy and safety of dose optimization of vedolizumab IV, compared with standard dosing of vedolizumab IV, over a 30-week treatment period. This study will enroll adult subjects with moderately to severely active ulcerative colitis (UC) who are eligible for ...

Phase